CHP
OCUL icon

Cable Hill Partners’s Ocular Therapeutix OCUL Stock Holding History

Cable Hill Partners’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-100
Closed – – 833
2018
Q4 		$0 Sell
100
-900
-90% -$4.96K ﹤0.01% 821
2018
Q3 		$7K Buy
+1,000
New +$6.28K ﹤0.01% 493

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Cable Hill Partners's OCUL Position: Q1 2019 in Review

Cable Hill Partners sold out of Ocular Therapeutix (OCUL) in Q1 2019, closing a stake of 100 shares.

Cable Hill Partners first reported a position in OCUL in Q3 2018 and held it in 2 quarters. The position peaked at $7K in Q3 2018. 68 funds tracked by Wall St. Rank hold OCUL as of Q1 2019.

  • Cable Hill Partners reported no remaining Ocular Therapeutix position as of Q1 2019 after selling out during the quarter.
  • Cable Hill Partners sold 100 Ocular Therapeutix shares in Q1 2019.
  • Cable Hill Partners first reported a position in Ocular Therapeutix in Q3 2018 and held it in 2 quarters.
  • Cable Hill Partners's Ocular Therapeutix position peaked at $7K in Q3 2018.
  • 68 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2019.

Based on Cable Hill Partners's 13F filing for Q1 2019, filed 10 May 2019.